1. Introduction {#sec1}
===============

Breast cancer is the most common cancer in women worldwide \[[@B1]\]. It is a multifactorial disease caused by complex genetic and environmental factors \[[@B2]\]. Allele variants in oncogenes are candidate genetic risk factors that may alter breast cancer onset and outcome. Previous researches have suggested that the risk of breast cancer is affected by multiple environmental factors as well as genetic alterations, such as genetic polymorphisms \[[@B3], [@B4]\].

Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthetase (PTGS), plays an important role in the inflammatory process by converting arachidonic acid to prostaglandins (PG) \[[@B5]\]. There are two COX isoforms: COX-1 and COX-2. COX-1 is present in many tissues and is involved in PG synthesis. By contrast, COX-2 is not detected in most normal tissues but is often overexpressed in many tumor types \[[@B6]\]. COX-2 can be rapidly induced by a variety of mitogenic and inflammatory stimuli and elevate the production of prostaglandins, which contribute to tumor occurrence and progression by modulating cell proliferation, apoptosis, and angiogenesis \[[@B6]--[@B8]\]. In breast cancer, several studies have suggested that moderate to high COX-2 expression is related to the genesis of mammary tumors and the expression level is associated with the aggressiveness of breast cancer, including large tumor size, positive axillary lymph node metastases, and HER2-positive tumor status \[[@B9]--[@B11]\]. Targeted inhibition of COX-2 blocked the proliferation of breast cancer cell lines*in vitro* and prevented the occurrence of rat breast cancer chemically induced by DMBA \[[@B12]\].

Genetic polymorphisms in COX-2 have been shown to alter its expression and influence the susceptibility to various carcinomas \[[@B13], [@B14]\], including breast cancer \[[@B15]\]. The human COX-2 gene (also known as PTGS2) is located on chromosome 1q25.2-q25.3 and consists of 10 exons spanning 8.3 kb \[[@B16]\]. Several single-nucleotide polymorphisms (SNPs) in COX-2 have been identified, of which three functional SNPs, −765 G\>C (rs20417), −1195G\>A (rs689466) in the promoter region, and the 8473 C\>T (rs5275) in the 3′UTR of COX-2, have been widely investigated \[[@B13]--[@B15]\].

Previous functional studies have suggested that the rs20417 polymorphism may eliminate a Sp1-binding site but create an E2F binding site and result in altered COX-2 expression \[[@B13]\]. The rs5275 polymorphism was shown to be associated with the alteration of mRNA level of the gene as sequences within the 3′UTR are important for message stability and translational efficiency \[[@B17]\]. There are many studies that have investigated the association between COX-2 polymorphisms and breast cancer risk. However, the results are inconsistent. For example, Fawzy et al. reported that rs5275 polymorphism was associated with the BC in Egyptian women. The individuals with rs5275 CC genotypes showed significant increase in plasma PGE2 levels \[[@B18]\]. However, Brasky et al. demonstrated that rs5275 had no association with breast cancer risk in Caucasians \[[@B19]\]. In our previous study, variant genotypes of COX-2 rs20417 G\>C (GC/CC) were associated with increased breast cancer risk. Furthermore, the increased risk was more prominent among the younger subjects (OR = 1.61, 95% CI = 1.00--2.61). The variant genotypes were also associated with tumor size (OR = 3.01, 95% CI = 1.47--6.12) \[[@B20]\].

To clarify the role of COX-2 polymorphisms in breast cancer risk, Yu et al. conducted a meta-analysis on the associations between several COX-2 polymorphisms and breast cancer risk. The results suggested borderline increased risk of breast cancer with rs5277 but no significant associations with the rs20417 and rs5275 polymorphisms \[[@B15]\]. However, of the studies included in their meta-analysis, only two studies were carried out in Asians \[[@B21], [@B22]\] and the rs689466 polymorphism was not involved. To make a more precise estimation, we conduct the present meta-analysis on all eligible case-control studies to evaluate the association between the three common SNPs (rs20417, rs689466, and rs5275) and breast cancer susceptibility.

2. Materials and Methods {#sec2}
========================

2.1. Publication Search {#sec2.1}
-----------------------

We searched the electronic databases of PubMed, Web of Knowledge, and Embase to collect articles with case-control studies related to the association of COX-2 polymorphisms with breast cancer risk. The keywords were as follows: breast cancer/breast carcinoma, Cyclooxygenase-2/COX-2/PTGS, and polymorphism/genotype/SNP. All qualified studies prior to February 28, 2014, were included. The eligible literature must be published in English. Furthermore, reference lists of main reports and review articles were also reviewed manually to identify additional relevant publications.

2.2. Selection Criteria {#sec2.2}
-----------------------

The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.

2.3. Data Extraction and Synthesis {#sec2.3}
----------------------------------

Articles were reviewed independently by two reviewers and data with discrepancies were discussed by all authors. For each included study, the following information was collected: first author, year of publication, country of origin, ethnicity, source of control, total number of cases and controls, and genotyping methods as well as number of cases and controls with the different genotypes. Different ethnic groups were categorized as Caucasian, Asian, African, and "mixed." All the case and control groups were well controlled. The noncancer controls had no history of gynecologic disease, and there was no present evidence of any malignant disease. The histories of chronic inflammatory condition or other malignancies of the patients were not considered in this study.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The associations between COX-2 polymorphisms and breast cancer risk were measured by odds ratio (OR) with 95% confidence interval (CI). The significance of the pooled OR was determined by the *Z* test.

The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model---the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model---the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model---comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model---the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where "a" is the wild-type allele and "A" is the variant allele)).

Statistical heterogeneity among studies was assessed with the *Q* and *I* ^2^ statistics. If the *P* value of heterogeneity test was more than 0.1 (*P* ≥ 0.1), the pooled OR estimate of the study was calculated by the fixed-effects model. Otherwise, the random-effects model was used \[[@B11]\]. The value of the *I* index is used to assess the degree of heterogeneity (*I* ^2^ \< 25%: no heterogeneity; 25% \< *I* ^2^ \< 50%: moderate heterogeneity; 50% \< *I* ^2^ \< 75%: high heterogeneity; *I* ^2^ \> 75%: extreme high heterogeneity). Publication bias was evaluated by the funnel plot and further assessed by the method of Egger\'s linear regression test. All statistical analyses were carried out with the review manager version 5.1 (Revman; The Cochrane Collaboration, Oxford, UK).

3. Results {#sec3}
==========

3.1. Characteristics of Studies {#sec3.1}
-------------------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, a total of 378 potential publications were initially extracted. After reading the abstracts, we excluded 176 irrelevant studies, 113 studies with insufficient data, and 53 duplicated ones. In-depth reading of the remaining articles led to further exclusion of 12 articles with no detailed genotyping data, 6 studies with no case-control, 3 laboratory studies, and 4 systematic review articles. Finally, 13 studies from 11 articles were collected for this meta-analysis.

Overall, 13 studies on COX-2 polymorphisms and breast cancer risk were identified \[[@B16], [@B18]--[@B28]\], including a total of 15,330 cases and 19,260 case-free controls. The characteristics of the included studies are listed in [Table 1](#tab1){ref-type="table"}. Among the eligible 13 studies, nine studies were carried out in Caucasians from USA, Austria, Denmark, Brazil, and nine European countries. Two were based on Asian background and were carried out in China. Only one study carried out in Egypt was based on African background. One study was on mixed ethnic groups. All studies were case-controlled. All breast cancers were confirmed by histology or pathology. Moreover, controls were mainly matched by age. Five studies were hospital-based and eight were population-based.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

As shown in [Table 2](#tab2){ref-type="table"}, the frequencies of the minor allele varied widely across the eligible studies, ranging from 0.06 to 0.28 (rs20417), 0.12 to 0.54 (rs689466), and 0.18 to 0.45 (rs5275). The average frequencies of the minor allele in the three polymorphisms were 0.17, 0.22, and 0.33, respectively.

The main results of this meta-analysis were listed in [Table 3](#tab3){ref-type="table"}. There were 6 studies with 9,938 cases and 12,618 controls for rs20417. As shown in [Table 3](#tab3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}, rs20417 polymorphism has association with breast cancer risk in the overall population based on homozygote comparison (CC versus GG: OR = 1.21, 95% CI = 1.02--1.42, *P* = 0.03) and the recessive model (CC versus GG + GC: OR = 1.22, 95% CI = 1.03--1.43, *P* = 0.02). However, there are no significant associations in other genetic models (C versus G: OR = 1.04, 95% CI = 0.98--1.10, *P* = 0.17; heterozygote comparison (GC versus GG): OR = 0.97, 95% CI = 0.91--1.03, *P* = 0.35; dominant model (GC + CC versus GG): OR = 1.01, 95% CI = 0.96--1.08, *P* = 0.64). In the stratified analysis by ethnicity, the effects remained in Caucasians (homozygote comparison: OR = 1.20, 95% CI = 1.02--1.42, *P* = 0.03; recessive model: OR = 1.21, 95% CI = 1.03--1.43, *P* = 0.02), but not in Asians ([Table 3](#tab3){ref-type="table"}).

There were 4 studies with 8,214 cases and 10,202 controls for assessing the relationship between COX-2 rs689466 polymorphism and breast cancer susceptibility. As shown in [Table 3](#tab3){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94--1.04, *P* = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88--1.15, *P* = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92--1.05, *P* = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89--1.15, *P* = 0.85). However, rs689466 polymorphism has association with breast cancer risk based on the recessive model (AA + AG versus GG: OR = 0.90, 95% CI = 0.87--0.95, *P* = 0.002). In the stratified analysis, when analyzed by the dominant model, the OR was 0.88 (95% CI = 0.83--0.94) (*P* \< 0.0001) among Caucasians. These results suggested that the individuals with AA or AG alleles have a 12% decreased risk of breast cancer compared with those with GG allele in Caucasians.

13 studies with 15,017 cases and 18,901 controls were used to evaluate the relationship between COX-2 rs5275 polymorphism with breast cancer risk. As shown in [Table 3](#tab3){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96--1.12, *P* = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95--1.04, *P* = 0.81; dominant model: OR = 1.02, 95% CI = 0.98--1.07, *P* = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97--1.12, *P* = 0.27). When stratified by ethnicity, there was also no association between rs5275 and breast cancer risk in both Caucasians and Asians ([Table 3](#tab3){ref-type="table"}).

3.3. Publication Bias {#sec3.3}
---------------------

In this meta-analysis, we performed funnel plot and Egger\'s test to access the publication bias. As shown in [Figure 5](#fig5){ref-type="fig"}, the funnel plots failed to detect any obvious asymmetry in all genotypes in overall population, and the results of Egger\'s test revealed no publication bias (*P* \> 0.05). Therefore, no significant publication bias was found in this meta-analysis.

4. Discussion {#sec4}
=============

The present meta-analysis, including 15,330 cases and 19,260 controls from 13 case-control studies, was conducted to evaluate the association between the three common SNPs \[−765 G\>C (rs20417), −1195 G\>A (rs689466), and 8473 C\>T (rs5275)\] in the COX-2 gene and breast cancer risk.

A previous study by Yu et al. \[[@B15]\] failed to detect an association between rs20417 and breast cancer risk. There were only three studies with 2,901 cases and 3,463 controls for rs20417 in Yu\'s meta-analysis \[[@B15]\]. In this study, there were six studies with 9,938 cases and 12,618 controls included to evaluate the relationship between rs20417 polymorphism and breast cancer risk. The results showed that rs20417 polymorphism was associated with breast cancer risk in the overall population based on homozygote comparison (CC versus GG: OR = 1.21, 95% CI = 1.02--1.42, *P* = 0.03). Moreover, in a stratified analysis by ethnicity using the recessive model, we found that the association remained in Caucasians (homozygote comparison: OR = 1.20, 95% CI = 1.02--1.42, *P* = 0.03; recessive model: OR = 1.21, 95% CI = 1.03--1.43, *P* = 0.02), but not in Asians. These results suggest ethnic differences in genetic backgrounds and the environment in which they live play a possible role in breast carcinogenesis \[[@B29]\].

In Zhu et al.\'s meta-analysis \[[@B30]\], they showed that individuals with the rs20417 were associated with higher cancer risk than those with the −765GG genotype. Stratified analysis further revealed that this effect was maintained in colorectal carcinoma and esophageal cancer in Asian descents. However, the rs5275 polymorphism was not associated with cancer risk although in breast and lung cancer this allele was correlated with decreased risk.

In the present meta-analysis, 13 studies with 15,017 cases and 18,901 controls concerning the rs5275 polymorphism were included. We found no significant association of rs5275 polymorphism with breast cancer risk (homozygote comparison: OR = 1.04, 95% CI = 0.96--1.12, *P* = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95--1.04, *P* = 0.81; dominant model: OR = 1.02, 95% CI = 0.98--1.07, *P* = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97--1.12, *P* = 0.27). When stratified by ethnicity, similar results were observed in both Caucasians and Asians.

In the previous meta-analysis by Tang et al. \[[@B14]\], there was an association of the rs689466 polymorphism with cancer risk in Asian populations but not in Europeans. Our results indicate that rs689466 polymorphism has association with breast cancer risk based on the recessive model (AA + AG versus GG: OR = 0.90, 95% CI = 0.87--0.95, *P* = 0.002). In the stratified analysis, when analyzed by the dominant model, the OR was 0.88 (95% CI = 0.83--0.94) (*P* \< 0.0001) among Caucasians.

Some limitations of this meta-analysis should be noted. Firstly, this meta-analysis was based on pooled data and no individual data was available; thus, we could not assess the risk of cancer according to stratification by age, environment factors, and other risk factors of breast cancer. Secondly, most of the included studies did not investigate the chronic inflammatory condition and the history of taking nonsteroidal anti-inflammatory drugs. Thirdly, the included studies are mainly based on Caucasian background. There were only two studies based on Asian background and one based on African background. Larger scale multicenter studies based on Asians or Africans are warranted to further validate the association between COX-2 polymorphisms and breast cancer risk.

5. Conclusion {#sec5}
=============

In summary, this meta-analysis points to the COX-2 rs20417 C allele as a risk factor for breast cancer among Caucasian subjects. On the contrary, the rs689466 allele has a decreased risk of breast cancer in Caucasians. The rs5275 C status does not seem capable of predicting breast cancer risk in both Caucasians and Asians.
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![Flow chart of studies selection in this meta-analysis.](DM2014-484729.001){#fig1}

![. Forest plots of COX-2 rs20417 polymorphism and breast cancer risk in the overall population (CC versus GG + GC). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](DM2014-484729.002){#fig2}

![Forest plots of COX-2 rs689466 polymorphism and breast cancer risk in the overall population (AA + AG versus GG). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](DM2014-484729.003){#fig3}

![Forest plots of COX-2 rs5275 polymorphism and breast cancer risk in the overall population (TT + TC versus CC). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](DM2014-484729.004){#fig4}

![Funnel plot assessing evidence of publication bias from the eligible studies. (a) −765 G\>C (rs20417); (b) −1195G\>A (rs689466); and (c) 8473 C\>T (rs5275).](DM2014-484729.005){#fig5}

###### 

Characteristics of the studies included in the meta-analysis.

  First author               Year   Country       Ethnicity   Study design   Genotyping method   Source of control   Total sample size (case/control)   SNP number
  -------------------------- ------ ------------- ----------- -------------- ------------------- ------------------- ---------------------------------- ------------
  Gao \[[@B20]\]             2014   China         Asian       CC             TaqMan              Hospital            465/799                            1, 3
  Fawzy \[[@B18]\]           2013   Egypt         African     CC             PCR-RFLP            Hospital            160/150                            3
  Brasky \[[@B19]\]          2011   USA           Caucasian   CC             TaqMan              Population          1077/1910                          2, 3
  Piranda \[[@B16]\]         2010   Brazil        Caucasian   CC             TaqMan              Population          318/273                            1, 2, 3
  Dossus \[[@B23]\]          2010   USA, Europe   Caucasian   CC             Illumina            Population          6292/8135                          1, 2, 3
  Abraham \[[@B24]\]         2009   EPIC          Caucasian   CC             TaqMan              Population          2200/2280                          3
  Gao \[[@B21]\]             2007   China         Asian       CC             PCR-RFLP            Hospital            601/643                            1, 2, 3
  Cox 1 \[[@B25]\]           2007   USA           Caucasian   CC             TaqMan              Population          1270/1762                          1, 3
  Cox 2 \[[@B25]\]           2007   USA           Caucasian   CC             TaqMan              Population          317/634                            3
  Cox 3 \[[@B25]\]           2007   USA           Caucasian   CC             TaqMan              Population          702/703                            3
  Vogel \[[@B26]\]           2007   Denmark       Caucasian   CC             TaqMan              Hospital            361/361                            3
  Langsenlehner \[[@B27]\]   2006   Austria       Caucasian   CC             TaqMan              Hospital            500/500                            3
  Shen \[[@B28]\]            2006   USA           Mixed       CC             PCR-RFLP            Population          1067/1110                          1, 3

CC: case-control; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism. EPIC: European Prospective Investigation of Cancer (a prospective study of diet and cancer being carried out in nine European countries). SNP: single-nucleotide polymorphisms; SNP number 1: −765G\>C (rs20417); 2: −1195G\>A (rs689466); 3: 8473T\>C (rs5275).

###### 

COX-2 polymorphisms genotype distribution and allele frequency in cases and controls.

  First author                     Genotype (*N*)   Allele frequency (*N*)   MAF                                                                    
  -------------------------------- ---------------- ------------------------ ------ ------ ------ ------ ------ ----- ------- ------ ------- ------ ------
  rs20417                                                                                                                                            
   Gao 2014 \[[@B20]\]             465              394                      67     4      799    719    76     4     855     75     1514    84     0.08
   Piranda 2010 \[[@B16]\]         308              157                      127    24     264    129    117    18    441     175    375     153    0.28
   Dossus 2010 \[[@B23]\]          6254             4394                     1646   214    8092   5694   2166   232   10434   2074   13554   2630   0.17
   Gao 2007 \[[@B21]\]             601              526                      73     2      643    582    59     2     1125    77     1223    63     0.06
   Cox 1 2007 \[[@B25]\]           1243             865                      336    42     1715   1185   485    45    2066    420    2855    575    0.17
   Shen 2006 \[[@B28]\]            1067             670                      387    1105   691    414    ---    ---   ---     ---    ---            
  rs689466                                                                                                                                           
   Brasky 2011 \[[@B19]\]          1077             660                      271    34     1910   1199   471    54    1591    339    2869    579    0.18
   Piranda 2010 \[[@B16]\]         289              224                      62     3      245    190    51     3     510     68     431     57     0.12
   Dossus 2010 \[[@B23]\]          6247             4020                     1928   299    8115   5143   2562   410   9968    2526   12848   3382   0.20
   Gao 2007 \[[@B21]\]             601              121                      305    175    643    150    327    166   547     655    627     659    0.54
  rs5275                                                                                                                                             
   Gao 2014 \[[@B20]\]             465              299                      132    34     799    515    244    40    730     200    1274    324    0.22
   Fawzy 2013 \[[@B18]\]           160              53                       71     36     150    69     67     14    177     143    205     95     0.45
   Brasky 2011 \[[@B19]\]          1077             432                      447    108    1910   732    782    226   1311    663    2246    1234   0.31
   Piranda 2010 \[[@B16]\]         294              125                      149    20     244    120    99     25    399     189    339     149    0.32
   Dossus 2010 \[[@B23]\]          6133             2697                     2664   772    7946   3512   3501   933   8058    4208   10525   5367   0.34
   Abraham 2009 \[[@B24]\]         2172             927                      985    260    2265   996    1010   259   2839    1505   3002    1528   0.35
   Gao 2007 \[[@B21]\]             601              404                      179    18     643    429    194    20    987     215    1052    234    0.18
   Cox 1 2007 \[[@B25]\]           1249             541                      567    141    1720   699    808    213   1649    849    2206    1234   0.34
   Cox 2 2007 \[[@B25]\]           301              140                      131    30     610    270    259    81    411     191    799     421    0.32
   Cox 3 2007 \[[@B25]\]           644              281                      296    67     651    278    294    79    858     430    850     452    0.33
   Vogel 2007 \[[@B26]\]           361              167                      150    44     361    155    165    41    484     238    475     247    0.33
   Langsenlehner 2006 \[[@B27]\]   500              214                      224    62     500    234    232    33    652     348    700     298    0.35
   Shen 2006 \[[@B28]\]            1060             475                      585    1102   467    635    ---    ---   ---     ---    ---            

A represents the major allele; B represents the minor allele. MAF: minor allele frequencies.

###### 

Meta-analysis of the association between COX-2 polymorphisms and breast cancer risk.

  Comparisons         OR         95% CI           *P* value      Heterogeneity   Effects model   
  ------------------- ---------- ---------------- -------------- --------------- --------------- -----
  B versus A                                                                                      
   rs20417            1.04       0.98--1.10       0.17           56%             0.06            R
    Caucasian         1.02       0.96--1.08       0.50           0%              0.92            F
    Asian             1.45       1.15--1.84       0.002          0%              0.47            F
   rs689466           0.99       0.94--1.04       0.69           33%             0.21            F
    Caucasian         0.97       0.92--1.03       0.34           0%              0.58            F
    Asian             1.14       0.97--1.33       ---            ---             ---             ---
   rs5275             1.01       0.98--1.05       0.50           56%             0.01            R
    Caucasian         1.00       0.97--1.04       0.80           41%             0.09            R
    Asian             1.03       0.89--1.19       0.70           0%              0.51            F
  BB versus AA                                                                                    
   rs20417            1.21       1.02--1.42       **0.03**       0%              0.97            F
    Caucasian         1.20       1.02--1.42       **0.03**       0%              0.92            F
    Asian             1.54       0.49--4.78       0.46           0%              0.68            F
   rs689466           1.01       0.88--1.15       0.93           22%             0.28            F
    Caucasian         0.95       0.82--1.10       0.52           0%              0.69            F
    Asian             1.31       0.95--1.80       ---            ---             ---             ---
   rs5275             1.04       0.96--1.12       0.34           66%             0.0008          R
    Caucasian         1.01       0.94--1.10       0.72           58%             0.01            R
    Asian             1.26       0.85--1.85       0.25           7%              0.30            F
  AB versus AA                                                                                    
   rs20417            0.97       0.91--1.03       0.35           93%             \<0.00001       R
    Caucasian         0.94       0.88--1.01       0.07           95%             \<0.00001       R
    Asian             **1.49**   **1.15--1.91**   **0.002**      0%              0.53            F
   rs689466           0.98       0.92--1.05       0.59           0%              0.59            F
    Caucasian         0.97       0.91--1.04       0.44           0%              0.74            F
    Asian             1.16       0.87--1.54       ---            ---             ---             ---
   rs5275             0.99       0.95--1.04       0.81           0%              0.56            F
    Caucasian         0.99       0.95--1.04       0.81           0%              0.47            F
    Asian             0.96       0.80--1.14       0.96           0%              0.78            F
  AB + BB versus AA                                                                               
   rs20417            1.01       0.96--1.08       0.64           54%             0.05            R
    Caucasian         1.00       0.93--1.06       0.93           0%              0.84            F
    Asian             1.49       1.16--1.91       0.002          0%              0.49            F
   rs689466           **0.90**   **0.87--0.95**   **0.0005**     94%             \<0.00001       R
    Caucasian         **0.88**   **0.83--0.94**   **\<0.0001**   96%             \<0.00001       R
    Asian             1.21       0.92--1.58       ---            ---             ---             ---
   rs5275             1.02       0.98--1.07       0.33           62%             0.002           R
    Caucasian         1.02       0.97--1.07       0.42           66%             0.002           R
    Asian             0.99       0.84--1.17       0.92           0%              0.86            F
  BB versus AA + AB                                                                               
   rs20417            **1.22**   **1.03--1.43**   **0.02**       0%              0.98            F
    Caucasian         **1.21**   **1.03--1.43**   **0.02**       0%              0.94            F
    Asian             146        0.47--4.56       0.51           0%              0.70            F
   rs689466           1.01       0.89--1.15       0.85           0%              0.48            F
    Caucasian         0.96       0.83--1.11       0.59           0%              0.76            F
    Asian             1.18       0.92--1.51       ---            ---             ---             ---
   rs5275             1.04       0.97--1.12       0.27           65%             0.0009          R
    Caucasian         1.02       0.95--1.10       0.60           60%             0.01            R
    Asian             1.28       0.87--1.87       0.21           15%             0.28            F

A: represents the major allele; B: represents the minor allele; F: fixed-effects model; R: random-effects model.
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